Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Debt / Equity

AKEBIA THERAPEUTICS, INC. (AKBA) Debt / Equity

  • 2026-06-30: Debt/Equity Ratio 1.98.
  • 2026-03-31: Debt/Equity Ratio 1.79.
  • 2025-12-31: Debt/Equity Ratio 1.48.
  • 2024-12-31: Debt/Equity Ratio -0.79.

Complete source-backed debt/equity ratio history.

Available history
2020-12-31 to 2026-06-30
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity Ratio
2026-06-301.98
2026-03-311.79
2025-12-311.48
2024-12-31-0.79
2024-09-30-0.76
2024-06-30-1.13
2024-03-31-1.11
2023-12-31-1.13
2023-09-30-1.08
2023-06-30-1.59
2023-03-31-2.63
2022-12-3112.63
2022-09-3015.97
2022-06-303.33
2021-12-311.32
2020-12-310.39

Annual Debt/Equity Ratio

DateDebt/Equity Ratio
2024-12-31-0.79
2023-12-31-1.13
2022-12-3112.63
2021-12-311.32
2020-12-310.39

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33